Norgine has made a significant move by acquiring Theravia, expanding its rare disease portfolio. This acquisition positions Norgine as a leading partner in the specialty pharma market.

Norgine's acquisition of Theravia enhances its rare disease pharmaceutical offerings, broadening access to innovative treatments across Europe.

Norgine's marketing authorisation of XOLREMDI® marks a significant advancement in treating WHIM syndrome, benefiting patients across the EU.

Norgine's recent EU marketing authorization for XOLREMDI® marks a significant step for WHIM syndrome patients, opening new treatment options.

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising rare and spe...

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

Key approval by the European Commission for Norgine's XOLREMDI® signifies a breakthrough for patients with WHIM syndrome, providing much-needed therapy.

Norgine's PEDMARQSI® has gained regulatory approval in Switzerland, marking a significant step in preventing cisplatin-induced hearing loss in pediatric patients. This innovative treatment addresses a critical medical need.

Norgine has received Swissmedic approval for PEDMARQSI, a groundbreaking treatment to prevent cisplatin-induced hearing loss in young cancer patients.

Norgine has announced that Swissmedic has approved PEDMARQSI®, the first treatment for preventing cisplatin-induced hearing loss in children, fulfilling an unmet medical need.

Norgine has announced that its drug PEDMARQSI® has received approval from Swissmedic to prevent cisplatin-induced hearing loss in children under 18.

Norgine invests £23 million in its Welsh facility, totaling over £50 million since 2022, enhancing medicine manufacturing and job creation.

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. Vir Biotechnology's chronic hepatitis delta treatment candidate has shown robust virological responses and reflects a differentiated...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine’s strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transac...